MED12 and prostate carcinoma: In addition, 2 independent datasets from CRISPR- and RNAi-based screens (DepMap portal) revealed that nearly all prostate cancer cell lines were highly sensitive to MED12 downregulation, suggesting its pivotal role in prostate cancer cell growth and survival.